Introduce BROMOCRIPTINE gradually, as follows: Week 1: 1mg to 1.25mg at bed time. The efficacy of low dose (5-30 mg/day) and high dose (31-100 mg/day) bromocriptine alone and with levodopa was examined in 27 studies encompassing 790 patients. However, BROMOCRIPTINE is capable of reducing elevated levels of growth hormone (GH) in patients with acromegaly. BROMOCRIPTINE offers particular benefit to patients on Levodopa treatment exhibiting a deteriorating therapeutic response or complications such as abnormal involuntary movements (choreoatoid dykinesia and/or painful dystonia), end-of-dose failure, and 'on-off' phenomenon.BROMOCRIPTINE improves the depressive symptomatology often observed in Parkinsonian patients. The following scheme is suggested: Initially, 1mg to 1.25mg at bed time, increasing after 2 to 3 days to 2mg to 2.5mg at bed time. These effects are due to stimulation of dopamine receptors.In the puerperium prolactin is necessary for the initiation and maintenance of puerperal lactation. Dosage may then be increased by 1mg at 2 to 3 day intervals, until a dosage of 2.5mg twice daily is achieved. Dosage may then be increased by 2.5mg daily at 2 to 3 day intervals, as follows:- 2.5mg eight hourly, 2.5mg six hourly, 5mg six hourly. Based on the outcome of more than 2,000 pregnancies, the use of BROMOCRIPTINE to restore fertility has not been associated with an increased risk of abortion, premature delivery, multiple pregnancy or malformation in infants. Metoclopramide and domperidone may reduce the prolactin-lowering effect.If pregnancy occurs it is generally advisable to withdraw BROMOCRIPTINE after the first missed menstrual period.Rapid expansion of pituitary tumours sometimes occurs during pregnancy and this may also occur in patients who have been able to conceive as a result of BROMOCRIPTINE therapy. In addition, BROMOCRIPTINE does not impair the puerperal involution of the uterus and does not increase the risk of thromboembolism.BROMOCRIPTINE has been shown to arrest the growth or to reduce the size of prolactin-secreting pituitary adenomas (prolactinomas).In acromegalic patients - apart from lowering the plasma levels of growth hormone and prolactin - BROMOCRIPTINE has a beneficial effect on clinical symptoms and on glucose tolerance.BROMOCRIPTINE improves the clinical symptoms of the polycystic ovary syndrome by restoring a normal pattern of LH secretion.Because of its dopaminergic activity, BROMOCRIPTINE, in doses usually higher than those for endocrinological indications, is effective in the treatment of Parkinson's Disease, which is characterised by a specific nigrostriatal dopamine deficiency. Date of first authorisation/renewal of the authorisationStart typing to retrieve search suggestions. Both in low doses and in high doses, bromocriptine combined with levodopa is usually more effective than bromocriptine alone. In the case of overdose, administration of activated charcoal is recommended and in the case of very recent oral intake, gastric lavage may be considered.The management of acute intoxication is symptomatic; Metoclopramide may be indicated for the treatment of emesis or hallucinations. They are considered to be due to the species-specific sensitivity of the test animals to the pharmacological activity of bromocriptine.Other effects in pre-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use. An oral dose of 5mg of bromocriptine results in a CThe substance is extensively metabolised in the liver. BROMOCRIPTINE is contraindicated for use in the suppression of lactation or other non-life threatening indications in patients with a history of coronary artery disease, or other severe cardiovascular conditions, or symptoms / history of severe psychiatric disorders.Patients with these underlying conditions taking BROMOCRIPTINE for the indication of macro-adenomas should only take it if the perceived benefits outweigh the potential risks (see Section 4.4 Special Warnings and Precautions). Rare: Pleural effusion, pleural and pulmonary fibrosis, pleuritis, dyspneoaVery Rarely: A syndrome resembling Neuroleptic Malignant Syndrome has been reported on withdrawal of BROMOCRIPTINE.